First 10 Drugs Selected for Medicare Negotiation

Back to Resources
AUTHOR – ATI Advisory

The Centers for Medicare & Medicaid Services announced the first 10 drugs to be negotiated by Medicare. As CMS and pharmaceutical manufacturers prepare for negotiations, they will consider not only the effectiveness of these drugs, but also their financial performance and investment over the years.

To create a public benchmark of these measures, ATI collected data from FDA labels, Evaluate Pharma and Omnium databases, the CMS spending dashboard, and proprietary data.

For each drug, we present a summary of its time on the market, use in Medicare, clinical development activity and investment, global and U.S. sales, its position in the manufacturer’s portfolio, and deal history.

Recent Work


Access to LTSS-Like Supplemental Benefits Data Brief

Many individuals in the United States access long term services and supports (LTSS) through Medicaid. But for Medicare beneficiaries without Medicaid, LTSS-like supplemental benefits offered by Medicare Advantage (MA) plans can help increase access to LTSS. This ATI Advisory data brief examines whether access to and enrollment in MA plans offering LTSS-like supplemental benefits differs meaningfully by demographic characteristics, including age, gender, race and ethnicity, and geography.
Read More Read More

Opportunities to Improve Quality of Life and Health Outcomes Among People Experiencing Incontinence

ATI analyzes the prevalence of incontinence among dual eligible individuals, and highlights services and products that can help individuals manage their incontinence.
Read More Read More

Pathways to Serve “Medicare-Onlys” Outside of PACE

Many Medicare beneficiaries could benefit from a model like Program of All-Inclusive Care for the Elderly (PACE) that offers comprehensive Medicare and Medicaid benefits to frail, older adults who want to remain living in the community. However, many older adults on Medicare do not have Medicaid coverage, making PACE less affordable to them.
Read More Read More
See more Work
LinkedIn / /